Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Selpercatinib with Chemotherapy in RET-Positive NSCLC (Lung-MAP S1900F)
NCT05364645Phase 2Withdrawn
- Sponsor
- SWOG Cancer Research Network
- Start
- Jul 2022
- Primary completion
- Jun 2023
- Modality
- Fragment-Derived Small Molecules, Reversible Covalent Inhibitors, Bivalent/Multivalent Binders
- Countries
- 1
01
Overview
A Phase 2 trial of selpercatinib in non-small cell lung cancer (NSCLC), sponsored by SWOG Cancer Research Network. Planned start Jul 2022; status: withdrawn.
02
Drugs
selpercatinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05364645.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05364645.